Paper39835546
Exploring the Therapeutic Potential of TROP2 Gene Silencing in Hepatocellular Carcinoma.
Yakoub F and 5 others. Recent Pat Biotechnol, 2026. Cited by 1 paper, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Exploring the Therapeutic Potential of TROP2 Gene Silencing in Hepatocellular Carcinoma. Papers, record 39835546. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39835546
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Hepatocellular | Major topic |
| Liver Neoplasms | Major topic |
| Antigens, Neoplasm | Major topic |
| Cell Adhesion Molecules | Major topic |
| Gene Silencing | Major topic |
| Humans | |
| Hep G2 Cells | |
| Cell Movement | |
| Apoptosis | |
| RNA, Small Interfering | |
| Patents as Topic | |
| Gene Expression Regulation, Neoplastic | |
| Gene Knockdown Techniques | |
| Tropomyosin |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| BC2191 | Theodor Bilharz Research Institute (TBRI), Giza, Egypt | PubMed |
Source PubMed
References31
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36891606 | The latest global burden of liver cancer: A past and present threat. | Clin Mol Hepatol | 2023 | https://conductscience.org/library/papers/36891606 | PubMed |
| 2 | 36208844 | Global burden of primary liver cancer in 2020 and predictions to 2040. | J Hepatol | 2022 | https://conductscience.org/library/papers/36208844 | PubMed |
| 3 | 37744303 | Egyptian Society of Liver Cancer Recommendation Guidelines for the Management of Hepatocellular Carcinoma. | J Hepatocell Carcinoma | 2023 | https://conductscience.org/library/papers/37744303 | PubMed |
| 4 | 35699406 | The advanced development of molecular targeted therapy for hepatocellular carcinoma. | Cancer Biol Med | 2022 | https://conductscience.org/library/papers/35699406 | PubMed |
| 5 | 35600358 | RNA Therapeutic Options to Manage Aberrant Signaling Pathways in Hepatocellular Carcinoma: Dream or Reality? | Front Oncol | 2022 | https://conductscience.org/library/papers/35600358 | PubMed |
| 6 | 36971908 | Oral delivery of RNAi for cancer therapy. | Cancer Metastasis Rev | 2023 | https://conductscience.org/library/papers/36971908 | PubMed |
| 7 | 38020299 | Immunohistochemical expression of TROP‑2 (TACSTD2) on the urothelial carcinoma of the urinary bladder and other types of cancer. | Oncol Lett | 2023 | https://conductscience.org/library/papers/38020299 | PubMed |
| 8 | 38203255 | The Relationship between Trop-2, Chemotherapeutic Drugs, and Chemoresistance. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/38203255 | PubMed |
| 9 | 7029529 | Human trophoblast cell-surface antigens defined by monoclonal antibodies. | Proc Natl Acad Sci U S A | 1981 | https://conductscience.org/library/papers/7029529 | PubMed |
| 10 | 36660684 | A literature review of the promising future of TROP2: a potential drug therapy target. | Ann Transl Med | 2022 | https://conductscience.org/library/papers/36660684 | PubMed |
| 11 | 36980630 | Overview of Trop-2 in Cancer: From Pre-Clinical Studies to Future Directions in Clinical Settings. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/36980630 | PubMed |
| 12 | 33187148 | Trop2: Jack of All Trades, Master of None. | Cancers (Basel) | 2020 | https://conductscience.org/library/papers/33187148 | PubMed |
| 13 | 38179054 | Targeting Trop2 in solid tumors: a look into structures and novel epitopes. | Front Immunol | 2023 | https://conductscience.org/library/papers/38179054 | PubMed |
| 14 | 37378943 | Immunohistochemical Expression of CD90, CD133, and TPM1 in Relation to Gastric Cancer and H. pylori Association. | Asian Pac J Cancer Prev | 2023 | https://conductscience.org/library/papers/37378943 | PubMed |
| 15 | 2440339 | Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. | Anal Biochem | 1987 | https://conductscience.org/library/papers/2440339 | PubMed |
| 16 | 23841653 | A new method for quantitative real-time polymerase chain reaction data analysis. | J Comput Biol | 2013 | https://conductscience.org/library/papers/23841653 | PubMed |
| 17 | 32723562 | Cyclin D-CDK4/6 functions in cancer. | Adv Cancer Res | 2020 | https://conductscience.org/library/papers/32723562 | PubMed |
| 18 | 36474748 | MicroRNA-122 mimic/microRNA-221 inhibitor combination as a novel therapeutic tool against hepatocellular carcinoma. | Noncoding RNA Res | 2023 | https://conductscience.org/library/papers/36474748 | PubMed |
| 19 | 38339417 | Management of Hepatocellular Carcinoma in 2024: The Multidisciplinary Paradigm in an Evolving Treatment Landscape. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38339417 | PubMed |
| 20 | 37814270 | Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation. | Mol Cancer | 2023 | https://conductscience.org/library/papers/37814270 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| TACSTD2 | 4070 | PubTator's text mining | https://conductscience.org/library/genes/4070 | NCBI Gene |
| TPM1 | 7168 | PubTator's text mining | https://conductscience.org/library/genes/7168 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39835546
GET https://conductscience.org/api/papers/v1/39835546/references?page=2